RNS Number : 7669H
ReNeuron Group plc
06 August 2021

ReNeuron Group plc

("ReNeuron" or the "Company")


Directorate Change

Appointment of Chief Financial Officer


ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Catherine Isted, ACMA, who will be joining the Board as Chief Financial Officer effective 11 October, 2021.


Ms. Isted is an experienced strategic finance professional and chartered accountant with 23 years' experience across the Healthcare industry. This includes 12 years at partner level in two leading Healthcare banking teams undertaking multiple Initial Public Offerings and follow-on fundraisings. Within the Healthcare industry, Ms. Isted has also held various in-house financial and strategic roles spanning Corporate Development, Investor Relations (IR) and Financial Planning and Analysis.


She is joining ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where Ms. Isted sits as part of the finance leadership team heading up the Corporate Development and IR. During her time working with the Group, as well as supporting potential board level strategic opportunities, she has been instrumental in raising in excess of £110 million for the Group over 3 tranches, transforming and internationalising the shareholder base, seeing the company grow 800% and enter the FTSE250. Ms. Isted has also held research analyst and equity sales positions in the Healthcare teams at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt.


Ms. Isted holds a 1st Class chemistry degree along with experience as a bench scientist, before moving into finance and training as an accountant at Merck. Ms Isted's career path has provided a highly differentiated and strategic view on the healthcare industry and will be invaluable to ReNeuron during a dynamic time for the Company.


Ian Ross, Chairman, commented: "Catherine has an excellent knowledge of the healthcare sector and is highly skilled in equity capital markets, M&A and strategic business development.  She will be a fantastic addition to the ReNeuron Board and I am thoroughly looking forward to working alongside her and welcoming her to the ReNeuron Board."


Olav Hellebø, CEO, commented: "I am delighted to welcome Catherine to the ReNeuron management team. Her extensive financial markets experience as well as her background as a healthcare analyst will be incredibly valuable going forward as the Company continues to grow."


Catherine Isted, incoming Chief Financial Officer commented: "I am delighted to be joining ReNeuron at what I think is an exciting time in the company's evolution, not only for the Groups lead stem cell programme in Retinitis Pigmentosa but also for their proprietary Exosomes and induced pluripotent stem cell (iPSC) platform technologies where there is growing excitement in the healthcare industry around their significant potential in a multiple of therapeutic areas. I look forward to working with the whole team and Board at ReNeuron to help realise the opportunity for the company in these leading fields of science."



Disclosures in accordance with the AIM Rules


Catherine Ann Isted, 46, is, or has been, a director or partner of the following companies or partnerships during the past five years:


Current Partnerships and Directorships:

Horne Grange Farm

Prior Partnerships and Directorships:

Peel Hunt LLP


Ms. Isted owns no shares in ReNeuron.


There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.







Olav Hellebø, Chief Executive Officer

Via Walbrook PR



Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600




Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)


Stefano Aquilino (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654


About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.


ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.


ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.